Looking for info on Manny Backus “Boston Biotech” Stock

WP Greet Box icon
Welcome! If you are new to Stock Gumshoe, grab a free membership here and join us to get our free newsletter alerts with new teaser answers and debunkings. Thanks!
Not new? Please log in at top right of this page

Hello Travis
Just saw a teaser about a ”Boston Biotech” stock that is poised to show 400 to 700% profits this year from Penny Stock gurus Manny Backus. Can you ”thinkolate” this one. Sounds pretty promising!
Thanks for your thoughts. They’re always appreciated!

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.

Email This Email This

4 Responses to Looking for info on Manny Backus “Boston Biotech” Stock

  1. Jeff,
    Greenfire67 is 100% correct on Ziopharm. Manny Backus wrote up a major article
    December 15, 2013 on it which you can read. He was promoting this stock on his Conscensus Picks which I still subscribe to. At that time he was advising subscribers
    to buy below $4 and to sell at $9. The drug in question is AD-RTS-IL-12 which is in
    phase two trials as of December 15, 2013. Also, the two partners that Ziopharm
    is working with are Intrexon (XON) and Mesoblast. The insider guy in the tease that
    bought 2,8577,000 shares for a cool ten million is Randall Kirk. They also issued 14.3 million shares last March which caused shares to plummet to $3.50 a stub. The title
    of the article is “Ziopharm: Finally a Cure in the War on Cancer?” which you can access
    by typing in ZIOP on the Finviz site, and scrolling down for this article below the stock
    chart. I’m not sure but Dr. Karma might have something to say about it in the Benitech


Leave a Reply

Your email address will not be published. Required fields are marked *

What These Icons Mean

  • The user who posted this comment is a Stock Gumshoe Premium Member (also known as an "IRREGULAR").
  • This user regularly writes articles for Stock Gumshoe. They may or may not be the author of the current article.
  • This user's comments have been "liked” by at least a few members of the Stock Gumshoe community.
  • This user has commented widely, with input that has been liked enough to earn a two-thumbs-up rating from other readers.
  • This is the highest rating a user can get. They are among the most respected commentors of our community.